210 related articles for article (PubMed ID: 26673747)
1. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
Yang XQ; Li CY; Xu MF; Zhao H; Wang D
BMC Cancer; 2015 Dec; 15():949. PubMed ID: 26673747
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; de Castria TB; Cruz MR; Riera R
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
Santos FN; Castria TB; Cruz MR; Riera R
Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
[TBL] [Abstract][Full Text] [Related]
5. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang S; Mao XD; Wang HT; Cai F; Xu J
BMJ Open; 2016 Jun; 6(6):e011714. PubMed ID: 27363819
[TBL] [Abstract][Full Text] [Related]
7. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
10. Second-line systemic therapy for metastatic colorectal cancer.
Mocellin S; Baretta Z; Roqué I Figuls M; Solà I; Martin-Richard M; Hallum S; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006875. PubMed ID: 28128439
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
12. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
16. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials.
Huang LT; Cao R; Wang YR; Sun L; Zhang XY; Guo YJ; Zhao JZ; Zhang SL; Jing W; Song J; Han CB; Ma J
BMC Cancer; 2021 Apr; 21(1):426. PubMed ID: 33865364
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer.
Murren JR; Andersen N; Psyrri D; Brandt D; Nadkarni R; Rose M; Davies MJ; Parisot N; Rosenfield AT; Pizzorno G; Zelterman D
Cancer Biol Ther; 2005 Dec; 4(12):1311-5. PubMed ID: 16258263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
